

1 Risk factors for long covid in previously hospitalised children using the

2 ISARIC Global follow-up protocol: A prospective cohort study

3 Ismail M Osmanov MD PhD^{1,2*}, Ekaterina Spiridonova BSc^{3*}, Polina Bobkova BSc^{3*}, Aysylu
4 Gamirova BSc^{3*}, Anastasia Shikhaleva BSc^{3*}, Margarita Andreeva BSc^{3*}, Oleg Blyuss
5 PhD^{3,4,*}, Yasmin El-Taravi BSc³, Audrey DunnGalvin PhD^{3,5}, Pasquale Comberiat MD⁶,
6 Diego G Peroni MD PhD⁶, Christian Apfelbacher PhD⁷, Jon Genuneit MD PhD⁸, Lyudmila
7 Mazankova MD PhD⁹, Alexandra Miroshina MD PhD¹, Evgeniya Chistyakova MD PhD¹⁰,
8 Elmira Samitova MD PhD^{1,9}, Svetlana Borzakova MD PhD^{2,11}, Elena Bondarenko³, Anatoliy A
9 Korsunskiy MD PhD³, Irina Konova MD¹, Sarah Wulf Hanson PhD¹², Gail Carson MD PhD¹³,
10 Louise Sigfrid MD PhD¹³, Janet T Scott MD PhD¹⁴, Matthew Greenhawt MD MBA¹⁵,
11 Elizabeth A Whittaker MD PhD¹⁶, Elena Garralda MD PhD¹⁷, Olivia Swann MD PhD^{18,19},
12 Danilo Buonsenso MD^{20,21,22}, Dasha E Nicholls MD PhD¹⁷, Frances Simpson MSc²³, Christina
13 Jones MD PhD²⁴, Malcolm G Semple MD PhD^{25,26}, John O Warner MD FMedSci²⁷, Theo Vos
14 PhD¹², Piero Olliaro MD PhD¹³, Daniel Munblit MD PhD^{3,27,28*} and Sechenov StopCOVID
15 Research Team

- 16 1. ZA Bashlyaeva Children's Municipal Clinical Hospital, Moscow, Russia
- 17 2. Pirogov Russian National Research Medical University, Moscow, Russia
- 18 3. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health,
19 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 20 4. School of Physics, Astronomy and Mathematics, University of Hertfordshire, College Lane,
21 Hatfield, United Kingdom
- 22 5. School of Applied Psychology, University College Cork, Cork City, Ireland
- 23 6. Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa,
24 Italy
- 25 7. Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke
26 University Magdeburg, Magdeburg, Germany
- 27 8. Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig,
28 Germany
- 29 9. Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of
30 the Russian Federation, Moscow, Russia
- 31 10. Department of Paediatrics and Paediatric Rheumatology, Institute of Child's Health, Sechenov
32 First Moscow State Medical University (Sechenov University), Moscow, Russia
- 33 11. Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare
34 Department, Moscow, Russia
- 35 12. Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
- 36 13. ISARIC Global Support Centre, Nuffield Department of Medicine, University of Oxford, Oxford,
37 UK
- 38 14. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
- 40 15. Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado,
41 University of Colorado School of Medicine, United States
- 42 16. Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK
- 43 17. Division of Psychiatry, Imperial College London, London, UK
- 44 18. Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
19. Royal Hospital for Children, Paediatric Infectious Diseases, Glasgow, UK

- 45
- 46 20. Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario
- 47 A. Gemelli IRCCS, Rome, Italy
- 48 21. Dipartimento di Scienze Biotechnologiche di Base, Cliniche Intensivologiche e Perioperatorie,
- 49 Università Cattolica del Sacro Cuore, Rome, Italy
- 50 22. Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Roma, Italia
- 51 23. Coventry University, Coventry, UK
24. School of Psychology, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK
- 52 25. Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection,
- 53 Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool,
- 54 Liverpool, UK
- 55 26. Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
- 56 27. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of
- 57 Medicine, Imperial College London, London, United Kingdom
- 58 28. Research and Clinical Center for Neuropsychiatry, Moscow, Russia
- 59

60 *Authors contributed equally to the paper.

61

62 **Corresponding author:**

63 Daniel Munblit, MD, PhD. Department of Paediatrics and Paediatric Infectious Diseases, Institute of

64 Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow,

65 Russia and Inflammation, Repair and Development Section, National Heart and Lung Institute,

66 Faculty of Medicine, Imperial College London, London, United Kingdom

67 Email: daniel.munblito8@imperial.ac.uk

68

69 **Sechenov StopCOVID Research Team (Group authors)**

70 Elina Abdeeva¹, Nikol Alekseeva¹, Anastasiia Bairashevskaya¹, Dina Baimukhambetova¹,
 71 Lusine Bazyants¹, Anna Berbenyuk¹, Tatiana Bezbabicheva¹, Julia Chayka¹, Salima
 72 Deunezhewa¹, Yulia Filippova¹, Svetlana Gadetskaya², Anastasia Gorina¹, Cyrill Gorlenko¹,
 73 Yulia V Ivanova², Margarita Kalinina¹, Bogdan Kirillov¹, Herman Kiseljow¹, Natalya Kogut¹,
 74 Mariia Korgunova¹, Anastasia Kotelnikova¹, Alexandra Krupina¹, Anna Kuznetsova¹,
 75 Anastasia Kuznetsova¹, Veronika Laukhina¹, Baina Lavginova¹, Elza Lidjieva¹, Nadezhda
 76 Markina¹, Daria Nikolaeva¹, Georgiy Novoselov¹, Polina Petrova¹, Erika Porubayeva¹, Kristina
 77 Presnyakova¹, Anna Pushkareva¹, Mikhail Rumyantsev¹, Ilona Sarukhanyan¹, Jamilya
 78 Shatrova¹, Nataliya Shishkina¹, Anastasia Shvedova¹, Valeria Ustyan¹, Maria Varaksina¹,
 79 Ekaterina Varlamova¹, Margarita Yegiyanyan¹, Elena Zuykova¹

80

81

- 82 1. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
 83 2. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health,
 84 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

85

86

87 *The names of the authors are in alphabetic order*

88

89

90

91 **Word count: 3,294**

92

93

94 ABSTRACT

95 **Background** The long-term sequelae of coronavirus disease 2019 (Covid-19) in children
96 remain poorly characterised. This study aimed to assess long-term outcomes in children
97 previously hospitalised with Covid-19 and associated risk factors.

98 **Methods** This is a prospective cohort study of children (≤ 18 years old) admitted with
99 confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow,
100 Russia. Children admitted to the hospital during the first wave of the pandemic, between
101 April 2, 2020 and August 26, 2020, were included. Telephone interview using the
102 International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-
103 19 Health and Wellbeing paediatric follow up survey. Persistent symptoms (> 5 months) were
104 further categorised by system(s) involved.

105
106 **Findings** Overall, 518 of 853 (61%) of eligible children were available for the follow-up
107 assessment and included in the study. Median age was 10.4 years (IQR, 3–15.2) and 270
108 (52.1%) were girls; median follow-up since hospital discharge was 256 (223–271) days. At the
109 time of the follow-up interview 126 (24.3%) participants reported persistent symptoms
110 among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29,
111 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%)
112 participants. Risk factors for persistent symptoms were: age “6–11 years” (odds ratio 2.74
113 (95% confidence interval 1.37 to 5.75) and “12–18 years” (2.68, 1.41 to 5.4), and a history of
114 allergic diseases (1.67, 1.04 to 2.67).

115
116 **Interpretation** A quarter of children experienced persistent symptoms months after
117 hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-
118 system involvement. Older age and allergic diseases were associated with higher risk of
119 persistent symptoms at follow-up. Our findings highlight the need for replication and further
120 investigation of potential mechanisms as well as clinical support to improve long term
121 outcomes in children.

122
123 **Funding** None.

Research in context

Evidence before this study

Evidence suggests that Covid-19 may result in short- and long-term consequences to health. Studies in children and adolescents are limited and available evidence is scarce. We searched Embase for publications from inception to April, 25, 2021, using the following phrases or combinations of phrases “post-covid condition” or “post-covid syndrome” or “covid sequalae” or “post-acute covid” or “long covid” or “long hauler” with “pediatric*” or “paediatric*” or “child*” or “infant*” or “newborn*” or “toddler*” or “neonate*” or “neonatal” or “adolescent*” or “teen*”. We found small case series and small cohort studies looking at Covid-19 consequences in children. No large cohort studies of previously hospitalised children, assessing symptom duration, categorisation or attempting multivariable analyses to identify independent risk factors for long Covid development were identified.

Added value of this study

To our knowledge, this is the largest cohort study with the longest follow-up since hospital discharge of previously hospitalised children. We found that even months after discharge from the hospital, approximately a quarter of children experience persistent symptoms with one in ten having multi-system involvement. Older age and allergic diseases are associated with Covid-19 consequences. Parents of some children report emotional and behavioural changes in their children after Covid-19.

Implications of all the available evidence

Our findings highlight the need for continued global research of Covid-19 consequences in the paediatric population. Older children admitted to the hospital should be carefully monitored upon discharge. Large, controlled studies aiming to identify risk groups and potential intervention strategies are required to fill knowledge gaps.

INTRODUCTION

The Covid-19 pandemic has, at the time of writing, affected over 135 million people worldwide ¹, with adverse impacts on physical and psychological health and over 3 million deaths. While our knowledge of the acute phase of the disease has increased over time, evidence on the longer-term health consequences of covid-19 is still limited. Emerging data suggest that a substantial proportion of people experience ongoing symptoms including fatigue and muscle weakness, breathlessness, and neurological problems more than 6 months after the acute phase ^{2,3}. This phenomenon is commonly referred to as ‘long Covid’, a term defined by patient groups, and also known as post-Covid syndrome, the post-Covid-19 condition ⁴ or ‘Covid long-haulers’ ^{5,6}. Recent population data from the UK reported that the highest prevalence of long Covid after 12 weeks was among those aged 25 to 34 years (18.2%) and lowest in the 2 to 11 years age bracket (7.4%)⁷.

Children and adolescents are at lower risk of severe Covid-19 illness compared to adults ⁸ and may present with a wide range of clinical features and symptoms at the time of hospital admission ⁹⁻¹¹. Data suggest that among children hospitalised with Covid-19, up to a third of patients require intensive care (ICU) ¹² with premature infants at higher risk¹⁰. Among children admitted to ICU, some experience single or multi-organ failure and many require respiratory support. A small number of patients develop a severe condition called multisystem inflammatory syndrome in children (MIS-C), which usually appears a few weeks after the acute infection ¹³. Evidence on post-acute covid condition and long term outcomes in children is still limited to small studies with more than half having at least one persisting symptom 4 months after covid-19 infection ¹⁴. However, a recent publication from Australia suggested that only 8% of children aged 0-19 years (median 3 years) had ongoing symptoms 3-6 months after predominantly mild covid-19 infection. The limitation of the study as acknowledged by the authors was the low age range. This mandates the inclusion larger numbers particularly of older children in future studies ¹⁵.

There is a need to assess the long-term consequences of Covid-19 in paediatric populations ¹⁶, to inform clinicians, researchers and public health experts and address the impacts of this condition on the quality of life (QoL) of those affected and their families and to inform discussions on vaccination of children. This cohort study aimed to investigate the incidence of and risk factors for long-term Covid-19 outcomes in children post-hospital discharge. We used the standardised follow-up data collection protocol developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric Covid-19 follow up working group ¹⁷.

METHODS

Study design, setting and participants

This is a prospective cohort study of children (≤ 18 years old) admitted with suspected or confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow, Russia. This large tertiary university hospital can accommodate up to 980 children at a time and served as the primary Covid-19 hospital for children residing in Moscow city. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, with reverse transcriptase polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection were included. The parents of these children were contacted between January 31, 2021 and February 27, 2021 to complete a follow up survey for this study.

The acute-phase data were extracted from electronic medical records (EMR) and the Local Health Information System (HIS) at the host institution. The acute-phase dataset included demographics, symptoms, co-morbidities, chest computer tomography (CT), supportive care, and clinical outcomes at discharge. This study was approved by the Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74). Parental consent was sought during hospital admission and consent for the follow-up interview was sought via verbal confirmation during telephone interview.

Information about the current condition and persisting symptoms was collected by trained medical students via telephone by interviewing the parent/carer of the child, using the version 1 of the ISARIC COVID-19 Health and Wellbeing Follow Up Survey for Children, to assess patients' physical and psychosocial wellbeing and behaviour, with local adaptations, translated into Russian. The protocol was registered at The Open Science Framework¹⁸. The follow-up survey documented data on demographics, parental perception of changes in their child's emotional and behavioural status, previous vaccination history, hospital stay and readmissions, mortality (after the initial index event), history of newly developed symptoms between discharge and the follow-up assessment, including symptom onset and duration, and overall health condition compared to prior to the child's Covid-19 onset (**Supplementary file**). To assess the prevalence of symptoms over time parents were asked the following: (a) *Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the symptom/s)* and (b) *Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms.*

Interviews were undertaken by a team of medical students with experience gained in previous Covid-19 research^{3,19} who underwent standardised training in telephone assessment, REDCap data entry and data security. Assessments were conducted via interviews with the parents/carers. Non-responders were contacted by telephone three times before considering them lost to follow up.

Data management

REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) were used for data collection, storage and management^{20,21}. The baseline characteristics, including demographics, symptoms on admission and comorbidities were extracted from EMRs and entered into REDCap.

Exposure and outcome variables

For the purposes of this study, we defined “persistent symptoms” as symptoms present at the time of the follow-up interview and lasting for over 5 months. These were subcategorised into respiratory, neurological, sensory, sleep, gastrointestinal, dermatological, cardiovascular, fatigue and musculoskeletal (**Table S1**) informed by previously published literature^{22,23} and international expert group discussions.

Allergic diseases were defined as a presence of any of the following: asthma, allergic rhinitis, eczema or food allergy. Health status before Covid-19 and at the time of the interview was assessed using a 0 to 100 wellness scale²⁴, where 0 was the worst possible health and 100 the best possible health. Participants age categories were based on Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Pediatric Terminology²⁵. Severe disease was defined as having received non-invasive ventilation, invasive ventilation or admission to the paediatric intensive care unit (PICU) during the hospital admission.

Statistical analysis

Descriptive statistics were calculated for baseline characteristics. Continuous variables were summarised as median (with interquartile range) and categorical variables as frequency (percentage). The chi-squared test or Fisher’s exact test was used for testing hypotheses on differences in proportions between groups. The Wilcoxon rank-sum test was used for testing the hypotheses on differences between groups.

We performed multivariable logistic regression to investigate associations of demographic characteristics, co-morbidities (limited to those reported in $\geq 5\%$ of participants), presence of pneumonia during acute infection and severity of Covid-19 with persistent symptom categories presence at the time of the follow-up interview. We included all participants for whom the variables of interest were available in the final analysis, without imputing missing data. The differing denominators used indicate missing data. Odds ratios were calculated together with 95% confidence intervals (CIs).

Upset plots were used to present the coexistence of persistent symptom categories. Two-sided p-values were reported for all statistical tests, a p-value below 0.05 was considered to be statistically significant. Statistical analysis was performed using R version 3.5.1. Packages used included dplyr, lubridate, ggplots2, plotrix and UpSetR.

Patient and public involvement

The survey was developed by the ISARIC Global Paediatric Covid-19 follow up working group and informed by a wide range of global stakeholders with expertise in infectious diseases, critical care, paediatrics, epidemiology, allergy-immunology, respiratory medicine, psychiatry, psychology and methodology and patient representatives. The survey was distributed to the members of the patient group and suggestions from parents/carers were implemented.

RESULTS

Study population

All 853 children hospitalised with suspected Covid-19 to the hospital between April 2, 2020 and August 26, 2020 were discharged alive (**Figure 1**). Of 836 patients with accurate contact information, parents of 518 RT-PCR positive children agreed to be interviewed (response rate 62%) and were included in the analysis.




Figure 1. Flow diagram of patients with COVID-19 admitted to Z.A. Bashlyaeva Children's Municipal Clinical Hospital between April 2, 2020 and August 26, 2020.

The median age was 10.4 years (IQR, 3-15.2; range, 2 days–18 years), 272 (52.2%) were girls. Median follow-up time since hospital admission was 268 days (IQR 233-284). Children had a median of 8 (IQR, 4-9) years of formal school education and a median of 4 (IQR, 3-5) family members were residing in the household (**Table 1**).

Characteristics	Total (n=518)
Sex, female	270 (52.1%)
Age at the time of hospital admission, years (median, IQR)	10.4 (3-15.2)
Age (categorical), years	
<2	105 (20.3%)
2 – 5	80 (15.4%)
6 – 11	113 (21.8%)
12 – 18	220 (42.5%)
Days from discharge to follow-up (median, IQR)	256 (223-271)
Length of hospital admission (days, median, IQR)	10 (7-14)
Number of years of formal school education (median, IQR)	8 (4-9)
Number of members in household (median, IQR)	4 (3-5)
Pneumonia during hospitalisation	192/515 (37.3%)
Severe disease (non-invasive ventilation or invasive ventilation or PICU)	14/515 (2.7%)
Comorbidities	
Neurological disorders	43/514 (8.4%)
Neurodisability	11/514 (2.1%)
Heart diseases	21/514 (4.1%)
Haematological conditions	10/514 (1.9%)
Tuberculosis	9/514 (1.8%)
Respiratory diseases (not including asthma)	16/514 (3.1%)
Allergic diseases [†]	121/514 (23.5%)
Food Allergy	67/514 (13%)
Allergic Rhinitis	46/514 (8.9%)
Eczema	45/514 (8.8%)
Asthma (doctor diagnosed)	12/514 (2.3%)
Other skin problems (not including eczema)	8/514 (1.6%)
Gastrointestinal problems	48/514 (9.3%)
Oncological conditions	3/514 (0.6%)
Immune system diseases	6/514 (1.2%)
Genetic conditions	6/514 (1.2%)
Diabetes*	3/514 (0.6%)
Other endocrine illness (not diabetes)	12/514 (2.3%)
Renal/Kidney problems	18/514 (3.5%)
Excessive weight and obesity	25/514 (4.9%)
Malnutrition	10/514 (1.9%)
Rheumatological conditions	4/514 (0.8%)
Depression	4/514 (0.8%)
Anxiety	5/514 (1%)
HIV	0 (0%)
No comorbidities	284/514 (55.3%)
One comorbidity	141/514 (27.4%)
Two comorbidities or more	89/514 (17.3%)

Table 1. Demographic characteristics of patients admitted to the Z.A. Bashlyeva Children's Municipal Clinical Hospital. Data are n (%) or median (IQR) excluding missing values. *All cases of diabetes were type 1. †Allergic diseases include asthma, allergic rhinitis, food allergy and eczema.

The most common pre-existing comorbidity in this cohort was food allergy (13%, 67/514), followed by allergic rhinitis and asthma (9.7%, 50/514), gastrointestinal problems (9.3%, 48/514), eczema (8.8%, 45/514) and neurological problems (8.4%, 43/514). Parents of 55.3% (284/514) children did not report any comorbidities. Fever (83.6%, 427/511), cough (55.7%, 284/510), rhinorrhea (54.3%, 278/512) and fatigue (38.9%, 197/506) were the most common presenting symptoms at the time of the hospital admission (**Table S2**). 37.3%, 192/515 of patients had pneumonia during hospital stay, 2.7%, 14/515 had severe disease, which required non-invasive ventilation/invasive ventilation or admission to PICU. Treatments received during the hospital admission are presented in **Table S3**.

At the time of the follow-up interview, parents of 24.7% (128) children reported at least one persistent symptom, with fatigue 10.6% (53/496), insomnia 5.19% (26/501), disturbed smell 4.7% (22/467) and headache 3.5% (17/486) being the most common. Detailed information on symptoms and duration is presented in **Table S4**.

The prevalence of most symptoms declined over time. Prevalence of reported fatigue fell from 15.8% (82/518) at the time of discharge to 11.1% (55/496) 6-7 months later, altered sense of smell fell from 8.7% (45/518) to 5.4% (27/496), altered sense of taste from 5.6% (29/518) to 3.8% (19/496) and breathing difficulties from 3.9% (20/518) to 1.4% (7/496), respectively. However, no change was observed in the prevalence of sleep disturbances or headache over time. Changes in the prevalence of the most common symptoms from the time of discharge over the next 6-7 months are shown in **Figure 2**.





Figure 2. Prevalence of the most common symptoms after hospital discharge. The prevalence was calculated based on responses to the following questions: “Within the last seven days, has your child had any of these symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration of the symptom/s) and “Please report any symptoms that have been bothering your child since discharge that are not present today. Please specify the time of onset and duration of these symptoms.”

With regard to persistent symptom categories (**Table S1**), fatigue was the most commonly reported in 10.6% (53/498) of patients at the time of assessment, followed by sleep disturbance 7.2% (36/501), sensory problems 6.2% (29/467), gastrointestinal 4.4% (22/499) and dermatological 3.6% (18/496) problems. A smaller number of patients experienced neurological 3% (14/465), respiratory 2.5% (12/489), cardiovascular 1.9% (9/470) and musculoskeletal 1.8% (9/489) problems long-term.

A total of 8.5% (44) participants reported persistent symptoms from more than one category at the time of the follow-up assessment. Most commonly co-occurring categories were fatigue and sleep problems in 1.9% (10) of children, and fatigue and sensory problems were present in 1.5% (8) of participants. 2.7% (14) of children had persistent symptoms from three or more different categories. Co-existence of persistent symptom categories at the time of the follow-up is presented in the upset plot (**Figure 3**).




316
317 **Figure 3.** Upset plot representing coexistence of the persistent symptom (present at the time of the follow-up
318 interview and lasting for over 5 months) categories at the follow-up assessment. The values represent the number
319 of individuals experiencing a persistent symptom category or combination of categories. Black lines link multiple
320 symptoms indicated by black dots.

The scores on the wellness scale for children with one or two or more persistent symptoms significantly declined when compared to before Covid-19 onset from 90 (80-100) to 82.5 (70-93.8) and from 90 (80-95) to 70 (60-80) ($p < 0.001$ for all comparisons), respectively. Children who did not experience any persistent symptoms did not report any significant changes in wellness when asked to compare to how they felt before their acute Covid-19 illness. We also assessed emotional difficulties, social relationships, and activity levels in children (**Tables S4 - S5**). Parents related the following changes to Covid-19 illness, and not to the pandemic in general: less eating in 4.5% (23/512) of children, less sleeping in 3.5% (18/511) and more sleeping in 2% (10/511), reduced physical activity in 4.7% (24/512) and child becoming less emotional in 4.3% (22/511). In contrast, parents attributed changes to social activities to the pandemic in general rather than to the Covid-19 illness: 12% (58/485) of children were spending less time with their friends in person, while 13% (61/470) were spending more time with friends remotely, with less than one percent of parents attributing these changes to Covid-19 illness. 23% (110/478) of children were spending more time watching television, playing video/computer games or using social media for educational purposes, with 92.9% of parents associating these changes with the pandemic in general rather than the Covid-19 illness.

In multivariable regression analysis, older age group was associated with persistent symptoms. When compared with children under two years of ages, those ages 6-11 years had an odds ratio of 2.74 (95% confidence interval 1.37 to 5.75) of persistent symptoms and those 12-18 years of age (OR 2.68, 95% CI 1.41 to 5.4) both vs. <2 years. Another predictor associated with persistent symptoms was allergic diseases (OR 1.67, 95% CI 1.04 to 2.67). Similar patterns were seen for children with co-existence of persistent symptoms from 2 or more categories: 6-11 years of age (OR 2.49, 95% CI 1.02 to 6.72), 12-18 years of age (OR 3.18, 95% CI 1.43 to 8.11) both vs. <2 years.

A



B




Figure 4. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition. Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the time of follow-up and (B) two or more co-existing categories of persistent symptoms at the time of the follow-up. Abbreviation: CI, confidence interval.

DISCUSSION

To our knowledge, this is the largest prospective paediatric cohort study with the longest follow-up, assessing symptom prevalence and duration of long COVID in children and adolescents with laboratory confirmed SARS-CoV-2 infection post hospital discharge. We found that a quarter of children and adolescents had persistent symptoms at the time of the follow-up with fatigue, sleep disturbance and sensory problems being the most common. Almost one in ten reported multi-system impacts with two or more categories of persistent symptoms at the time of the follow-up. Children in mid-childhood and adolescence (age 6-18) were at higher risk of persistent symptoms at the time of the follow-up. Although prevalence of some symptoms declined over time, a substantial proportion experienced problems up to 7-8 months after discharge.

There are very few studies assessing long COVID in children and adolescents; a previous smaller study from Italy found similar persisting symptoms during a shorter follow-up²⁶. It is worth noting that although many parents reported nasal congestion/rhinorrhea in both studies, we found that nasal symptoms persisted long-term in a very small number of children. This highlights importance of symptom duration assessment as point prevalence of the symptom may not reflect its persistence and relevance to requirements for medical care and health/economics.

Although many children experienced symptoms, such as fatigue, disturbed smell and taste, sleep and respiratory problems, hair loss and headaches at the time of the hospital discharge, we witnessed a steady decline in the symptom prevalence over time. This was particularly evident for fatigue and smell disturbance. Prevalence of some symptoms such as headache, and sleep problems did not decline over time, which may be driven by psychological mechanisms rather than pathophysiologic virus infection effects²⁷. A limitation of these findings is that symptom onset and duration was recalled at the single follow-up interview in our study; this may be overcome with repeated follow-ups at appropriate intervals to limit potential recall imprecision. In line with our results, previous research demonstrated symptoms fading over time in adults²² but data are still limited as most of the published cohort studies do not measure symptom duration, but rather assess their presence at a single follow-up.

We found that almost one in ten children had multisystem impacts with two or more categories of persistent symptoms present at the time of the follow-up. Similar numbers were previously reported in the Russian adult population³ and patients with clusters of

different symptoms were described in the UK ²⁸. Patients with multisystem involvement will represent the primary target for the future research and intervention strategies development.

Age was significantly associated with persistent symptom presence at the time of the follow-up, with children above 6 years of age being at higher risk. To our knowledge, risk factors for long Covid in children have not been investigated in previous studies, so we may draw comparisons with the data from adult cohorts only. Previous data suggest that long Covid is prevalent in adults ^{2,3,28-31} and that age is associated with a higher risk of long Covid ^{28,30}. An Australian follow-up study of 151 children aged 0-19 years (median 3 years) who had predominantly mild acute covid-19 infection ¹⁵ found only 8% with on-going long-covid symptoms. As acknowledged by the authors the low median age may be the main reason for the low long-covid prevalence and our study substantiates this.

We found that allergic diseases in children were also associated with a higher risk of long Covid. This is in agreement with adult studies from Russia ³ and the UK ²⁸ reporting asthma to be associated with development of long Covid. Recent data suggested that COVID-19 consequences may be linked with the mast cell activation syndrome ³² and the Th-2 biased immunological response in children with allergic diseases may be responsible for an increased risk of long-term consequences from the infection. This highlights importance of further research of potential underlying immunological mechanisms of long Covid.

Apart from physical symptoms we assessed emotional and behavioural changes. Although most parents reported no changes, one in twenty parents noticed changes in their children, which they attributed to Covid-19 illness rather than the general situation during the pandemic. These included changes in eating, sleeping, emotional wellbeing and physical activities. Over one in ten parents noted that their children were spending less time in face-to-face communication and more time interacting with their friends remotely and spending time online for both educational and non-educational purposes. These changes were largely attributed to the general situation during the pandemic rather than to the Covid-19 illness. Of note, all surveyed children in our study had PCR-confirmed Covid-19 illness. It is possible, however, that the predominance in remote vs in person interactions will have longer term impacts in themselves. At present, to our knowledge, all publications on long Covid are uncontrolled cohorts due to the difficulties of ascertaining data among controls matched for age and sex but most importantly matched for the same experiences during the pandemic aside from confirmed Covid-19 illness. There is a need to conduct studies with reference groups of non-infected children to reliably assess mental health effects of the pandemic and distinguish them from Covid-19 infection consequences.

A major strength of this study is that it was based on the ISARIC COVID-19 Health and Wellbeing Follow Up Survey for Children which will assist with data harmonisation and comparison with other international studies in the future. Another strength is the large sample size of confirmed Covid-19 infected children, and this cohort has the longest follow-up assessment of hospitalised children to date. Stratification to determine if the symptoms were persistent following Covid-19 and assessment of trends over time were other novel aspects of the study. At the same time, this cohort study has several limitations. First, the study population only included patients within Moscow, although regional clustering is common to many cohort studies published during the Covid-19 pandemic. Second, it included only hospitalised children, not representative of paediatric population. Third, we did not have a control group of previously hospitalised children not experiencing Covid-19 infection. Fourth, some patients may have developed additional comorbidities or complications since the hospital discharge, which were not appropriately captured and could potentially affect the wellbeing and symptom prevalence and persistence. Fifth, the parents/caregivers were interviewed in this study and not children themselves. There is also a risk of recall bias in reporting symptoms which were non-existent at the time of the follow-up and potential selection bias with those with symptoms more likely to agree to survey.

Our findings have implications for further research. Longer follow up duration and repeated assessments combined with controls and sampling for further studies into the pathophysiology and immunology of post-Covid-19 illness sequelae are needed to inform case definitions, and intervention trials aimed to improve long term outcomes.

Although many symptoms which were present at discharge diminished over time, even eight months after hospital discharge many children experienced persistent symptoms, with fatigue, sensory changes and sleep problems being the most common sequelae. One in ten children experienced multi-system involvement at the time of the follow-up. Age and allergic disease were the main risk factors for persistent symptoms. Future work should be multidisciplinary, prospective, with a control cohort, repeated sampling and with an ability for children to report their health and wellbeing themselves, accompanied by biological sample collection to establish causative mechanisms for a better understanding of Covid-19 sequelae and help with the phenotype/endotype categorisation. Investigation of immunological aspects of the association between allergic diseases and long-covid development may identify mechanisms and therapeutic targets for management to mitigate potential adverse consequences.

Acknowledgments

We are very grateful to the Z.A. Bashlyaeva Children's Municipal Clinical Hospital clinical staff and to the patients, parents, carers and families for their kindness and understanding during these difficult times of COVID-19 pandemic. We would like to express our very great appreciation to ISARIC Global COVID-19 follow-up working group for the survey development. We would like to thank Mr Maksim Kholopov for providing technical support in data collection and database administration. We are very thankful to Eat & Talk, Luch, Black Market and Academia for providing us the workspace in time of need and their support of Covid-19 research. Finally, we would like to extend our gratitude to the Global ISARIC team, the ISARIC global adult and paediatric Covid-19 follow up working group, and ISARIC Global support centre for their continuous support, expertise and for the development of the outbreak ready standardised protocols for the data collection.

Funding statement

This study did not have external funding.

REFERENCES

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
2. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; **397**(10270): 220-32.
3. Munblit D, Bobkova P, Spiridonova E, et al. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. *medRxiv* 2021: 2021.02.17.21251895.
4. Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. *BMJ* 2021; **372**: n405.
5. Meeting the challenge of long COVID. *Nat Med* 2020; **26**(12): 1803.
6. The L. Facing up to long COVID. *The Lancet* 2020; **396**(10266): 1861.
7. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. 2021. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021> (accessed 6-th of April 2021).
8. Oualha M, Bendavid M, Berteloot L, et al. Severe and fatal forms of COVID-19 in children. *Arch Pediatr* 2020; **27**(5): 235-8.
9. Foster CE, Moulton EA, Munoz FM, et al. Coronavirus Disease 2019 in Children Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes. *J Pediatric Infect Dis Soc* 2020; **9**(3): 373-7.
10. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ* 2020; **370**: m3249.
11. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health* 2020; **4**(9): 653-61.

12. Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(32): 1081-8.
13. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med* 2020; **383**(4): 334-46.
14. Buonsenso D, Munblit D, De Rose C, et al. Preliminary Evidence on Long COVID in children. *medRxiv* 2021: 2021.01.23.21250375.
15. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* 2021.
16. Michelen M, Manoharan L, Elkheir N, et al. Characterising long-term covid-19: a rapid living systematic review. *medRxiv* 2020: 2020.12.08.20246025.
17. group IGPC-fuw. ISARIC Global COVID-19 paediatric follow-up. 2021. <https://isaric.org/research/covid-19-clinical-research-resources/paediatric-follow-up/> (accessed 24-th of April 2021).
18. Sigfrid L, Buonsenso D, DunnGalvin A, et al. Consequences of COVID-19 infection for child health and wellbeing: protocol for a prospective, observational, longitudinal study in children. 2021. <https://osf.io/d2wjin/> (accessed 21-st of April 2021).
19. Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. *Clin Infect Dis* 2020.
20. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019; **95**: 103208.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; **42**(2): 377-81.
22. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* 2020: 2020.12.24.20248802.
23. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ* 2020; **370**: m3026.
24. Viner R, Gregorowski A, Wine C, et al. Outpatient rehabilitative treatment of chronic fatigue syndrome (CFS/ME). *Arch Dis Child* 2004; **89**(7): 615-9.
25. Williams K, Thomson D, Seto I, et al. Standard 6: Age Groups for Pediatric Trials. *Pediatrics* 2012; **129**(Supplement 3): S153-S60.
26. Buonsenso D, Munblit D, De Rose C, et al. Preliminary Evidence on Long Covid in children. *Acta Paediatr* 2021.
27. Crawley SA, Caporino NE, Birmaher B, et al. Somatic complaints in anxious youth. *Child Psychiatry Hum Dev* 2014; **45**(4): 398-407.
28. Sigfrid L, Drake TM, Pauley E, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2021: 2021.03.18.21253888.
29. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry* 2021.
30. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med* 2021.
31. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021; **372**: n693.
32. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020; **100**: 327-32.